BICX Quote, Financials, Valuation and Earnings

Encompass Health Corp. has a net margin of -127.28% compared to BioCorRx, Inc.'s net margin of 13.07%. BioCorRx, Inc.'s return on equity of -- beat Encompass Health Corp.'s return on equity of 24.73%.

BioCorRx, Inc. has a consensus price target of --, signalling upside risk potential of 213.73%. On the other hand Encompass Health Corp. has an analysts' consensus of $142.73 which suggests that it could grow by 31%. Given that BioCorRx, Inc. has higher upside potential than Encompass Health Corp., analysts believe BioCorRx, Inc. is more attractive than Encompass Health Corp..

BioCorRx, Inc. has a beta of 0.326, which suggesting that the stock is 67.352% less volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.727, suggesting its less volatile than the S&P 500 by 27.328%.

BioCorRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health Corp. offers a yield of 0.66% to investors and pays a quarterly dividend of $0.19 per share. BioCorRx, Inc. pays -- of its earnings as a dividend. Encompass Health Corp. pays out 13% of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCorRx, Inc. quarterly revenues are $635.2K, which are smaller than Encompass Health Corp. quarterly revenues of $1.5B. BioCorRx, Inc.'s net income of -$808.5K is lower than Encompass Health Corp.'s net income of $201.9M. Notably, BioCorRx, Inc.'s price-to-earnings ratio is -- while Encompass Health Corp.'s PE ratio is 19.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCorRx, Inc. is 4.27x versus 1.88x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Elite Health Systems, Inc. has a net margin of -127.28% compared to BioCorRx, Inc.'s net margin of --. BioCorRx, Inc.'s return on equity of -- beat Elite Health Systems, Inc.'s return on equity of -72.99%.

BioCorRx, Inc. has a consensus price target of --, signalling upside risk potential of 213.73%. On the other hand Elite Health Systems, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioCorRx, Inc. has higher upside potential than Elite Health Systems, Inc., analysts believe BioCorRx, Inc. is more attractive than Elite Health Systems, Inc..

BioCorRx, Inc. has a beta of 0.326, which suggesting that the stock is 67.352% less volatile than S&P 500. In comparison Elite Health Systems, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.465%.

BioCorRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elite Health Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCorRx, Inc. pays -- of its earnings as a dividend. Elite Health Systems, Inc. pays out -- of its earnings as a dividend.

BioCorRx, Inc. quarterly revenues are $635.2K, which are larger than Elite Health Systems, Inc. quarterly revenues of --. BioCorRx, Inc.'s net income of -$808.5K is higher than Elite Health Systems, Inc.'s net income of -$1.2M. Notably, BioCorRx, Inc.'s price-to-earnings ratio is -- while Elite Health Systems, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCorRx, Inc. is 4.27x versus 7.08x for Elite Health Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group, Inc. has a net margin of -127.28% compared to BioCorRx, Inc.'s net margin of 6.82%. BioCorRx, Inc.'s return on equity of -- beat Pediatrix Medical Group, Inc.'s return on equity of 19.95%.

BioCorRx, Inc. has a consensus price target of --, signalling upside risk potential of 213.73%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $21.33 which suggests that it could grow by 7.31%. Given that BioCorRx, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe BioCorRx, Inc. is more attractive than Pediatrix Medical Group, Inc..

BioCorRx, Inc. has a beta of 0.326, which suggesting that the stock is 67.352% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.358%.

BioCorRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCorRx, Inc. pays -- of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend.

BioCorRx, Inc. quarterly revenues are $635.2K, which are smaller than Pediatrix Medical Group, Inc. quarterly revenues of $493.8M. BioCorRx, Inc.'s net income of -$808.5K is lower than Pediatrix Medical Group, Inc.'s net income of $33.7M. Notably, BioCorRx, Inc.'s price-to-earnings ratio is -- while Pediatrix Medical Group, Inc.'s PE ratio is 10.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCorRx, Inc. is 4.27x versus 0.89x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

U.S. Physical Therapy, Inc. has a net margin of -127.28% compared to BioCorRx, Inc.'s net margin of 6.45%. BioCorRx, Inc.'s return on equity of -- beat U.S. Physical Therapy, Inc.'s return on equity of 8.4%.

BioCorRx, Inc. has a consensus price target of --, signalling upside risk potential of 213.73%. On the other hand U.S. Physical Therapy, Inc. has an analysts' consensus of $105.33 which suggests that it could grow by 26.53%. Given that BioCorRx, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe BioCorRx, Inc. is more attractive than U.S. Physical Therapy, Inc..

BioCorRx, Inc. has a beta of 0.326, which suggesting that the stock is 67.352% less volatile than S&P 500. In comparison U.S. Physical Therapy, Inc. has a beta of 1.301, suggesting its more volatile than the S&P 500 by 30.094%.

BioCorRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. U.S. Physical Therapy, Inc. offers a yield of 2.16% to investors and pays a quarterly dividend of $0.45 per share. BioCorRx, Inc. pays -- of its earnings as a dividend. U.S. Physical Therapy, Inc. pays out 126.62% of its earnings as a dividend.

BioCorRx, Inc. quarterly revenues are $635.2K, which are smaller than U.S. Physical Therapy, Inc. quarterly revenues of $202.7M. BioCorRx, Inc.'s net income of -$808.5K is lower than U.S. Physical Therapy, Inc.'s net income of $13.1M. Notably, BioCorRx, Inc.'s price-to-earnings ratio is -- while U.S. Physical Therapy, Inc.'s PE ratio is 58.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCorRx, Inc. is 4.27x versus 1.62x for U.S. Physical Therapy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.